Fresenius

IVI RMA To Acquire North American Operations of Eugin Group, Including Boston IVF, Creating a Leading North American Fertility Group

Retrieved on: 
Wednesday, November 8, 2023
Research, Nursing, Medical Devices, Hospitals, Health Technology, Other Health, Managed Care, General Health, Health, Science, Fertility, Harvard Medical School, Family, Physician, TRIO, Workplace, Organization, Mazda North American Operations, Acquisition, Growth, IVF, Boston Medical Center, Partnership, Tufts Medical Center, Culture, Reproductive medicine, Fresenius, Patient, RMA, IVI

IVI RMA, one of the largest reproductive medicine groups in the world, has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius.

Key Points: 
  • IVI RMA, one of the largest reproductive medicine groups in the world, has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius.
  • The strategic additions will grow IVI RMA to become a leading fertility group in North America and reinforce the company’s commitment to providing evidence-based fertility solutions with the greatest chance of success to the greatest number of patients.
  • “We are thrilled to welcome Boston IVF, its partner clinics and TRIO to the IVI RMA network as we continue to bring the best fertility science to more markets across North America,” said Javier Sanchez Prieto, CEO of IVI RMA.
  • In addition, we look forward to operational enhancements, including best-in-class electronic medical records technology and a prosperous partnership as we continue to grow in North America as part of IVI RMA.”

Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Retrieved on: 
Wednesday, October 18, 2023
Frankfurt Stock Exchange, Sale, NYSE, Internal Revenue Code, Medicine, Internal Revenue Code section 1031, Capital Square, WINCHESTER, Fresenius Medical Care, DST, Fresenius, FMS, New York Stock Exchange, DAX, Commercial property

*

Key Points: 
  • *
    "Capital Square has acquired a large number of medical buildings in the southeast for the Section 1031 DST exchange program," said Louis Rogers, founder and co-chief executive officer of Capital Square.
  • "Medical assets are well known for providing stable income, preservation of capital and capital appreciation.
  • Since 2018, Capital Square has taken 24 DST offerings full cycle that have resulted in an average 173.51% total return and an average 14.53% internal rate of return.
  • Located at 38 W. Jubal Early Dr., the single-story Winchester medical building was acquired by Capital Square in July 2016.

EQS-News: CompuGroup Medical bundles data-based solutions with ambulatory information systems and appoints Daniela Hommel as CFO

Retrieved on: 
Tuesday, October 17, 2023
Physician, Intelligence, Innovation, Helios, Fresenius, CHS, AIS, Artificial intelligence, CGM, KPMG, CFO, Patient, Pharmaceutical industry, Management

Studies show that for every hour doctors and their teams can devote to patients, they spend three to four hours on administrative work.

Key Points: 
  • Studies show that for every hour doctors and their teams can devote to patients, they spend three to four hours on administrative work.
  • AI-based solutions can significantly reduce such inefficiencies in healthcare for the benefit of patients.
  • Also effective as of March 2024, the Board of Directors appoints Daniela Hommel as Chief Financial Officer.
  • Until she joins CompuGroup Medical, CEO Michael Rauch will continue to be responsible for the CFO role on an interim basis.

Kain Capital-Backed PERA Hires Jenifer Stevie as CFO

Retrieved on: 
Wednesday, October 11, 2023
Senior, PwC, Software as a service, Fresenius, University, Growth, CFO, Patient, Management, Nursing

NEW YORK, Oct. 11, 2023 /PRNewswire/ -- PERA Holdings ("PERA" or "the Company"), a national manager of mid-sized regional hospice and palliative care providers, today announced it has appointed Jenifer Stevie as Chief Financial Officer. Ms. Stevie is the Company's second C-Suite hire in 2023, following Julia Rosen, who recently joined as Chief Information Officer. PERA is a portfolio company of Kain Capital, a New York-based private equity firm focused on the technology enablement of healthcare services companies. Both executives were sourced through Kain's proprietary network of industry contacts.

Key Points: 
  • PERA is a portfolio company of Kain Capital, a New York-based private equity firm focused on the technology enablement of healthcare services companies.
  • "Jenifer is an important addition to the PERA team," said Kris Stice, CEO of PERA.
  • Before joining PERA, Ms. Stevie was CFO of several divisions of Fresenius Medical Care North America, where she focused on SaaS, value-based care, and diversified healthcare services.
  • "We are thrilled to see Jenifer bring her skills to PERA," said Kunal Kain, Founder and Managing Partner at Kain Capital and Co-Chairman of PERA Holdings.

Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Pharmaceutical, Health, Amgen, Asthma, CMS, Etanercept, Fresenius (company), Prevalence, Diabetes, Trastuzumab, Ustekinumab, Medicare, Inflation, Chronic condition, Patient, Analysis, Conditional sentence, Biosimilar, Rheumatoid arthritis, Centers for Medicare & Medicaid Services, Research, EMA, Tocilizumab, Ophthalmology, Fresenius, Knowledge, Growth, FDA, Celltrion, Legislation, Welfare, Arthritis, COVID-19, Cancer, Medicare Part D, Competitive landscape, Novartis, AbbVie, Inflation Reduction Act of 2022, Teva Pharmaceuticals, Biogen, Rituximab, Education, Eating, IRA, Sale, Movement, Scott Richter, Local Investing Opportunity Network, Physician, Fine chemical, Generic drug, Vaccine, Pharmaceutical industry, Natalizumab, Adalimumab, Ranibizumab

The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • In these volatile market conditions, the biosimilars market is still expanding dramatically, and the outlook is as promising.
  • It provides a detailed analysis of biosimilar market dynamics, covering clinical trials, patent data, financial deals, and company profiling details.
  • In addition, this report provides analyst commentary on key trends, drivers, strategies, innovations, and regulations in the field of biosimilars.

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
New Drug Application, Nephrology, Fresenius, Dermatology, Dialysis, Civil service commission, Health care, Chronic kidney disease, Travel, Sale, Patient, KICK, NDD, AD, Itch, Medication, American Academy, Conference call, Research and development, Notalgia paresthetica, Atopic dermatitis, CSL, NP, G&A, CSL Vifor, European Commission, Investment, R, PMDA, KIND, Administration, CKD, Medicines and Healthcare products Regulatory Agency, Cara, Growth, Therapy, Conference, Acceleration, EST, Pharmaceuticals and Medical Devices Agency, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Music, Difelikefalin, EU

STAMFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • During the fourth quarter of 2022, we saw both new clinic and repeat orders driving product uptake, bolstering our confidence in KORSUVA’s long-term potential,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • In the fourth quarter of 2022, wholesalers shipped 20,844 vials to dialysis centers following initial inventory building in the third quarter of 2022, predominantly at Fresenius clinics.
  • The Company expects launches in countries in Europe to continue in 2023, following launches of Kapruvia in Austria, Germany, and Sweden during the fourth quarter of 2022.
  • With the approval of Kapruvia in Australia in the fourth quarter of 2022, all four Access Consortium countries have approved the product.

Healthcare Workers File Petition Asking FDA to Recall Fresenius Dialysis Machines to Protect Patients

Retrieved on: 
Friday, January 20, 2023
Dizziness, Language, Heart, Fresenius Medical Care, Commissioner, SEIU, Food and Drug Administration Amendments Act of 2007, Death, Headache, SEIU United Healthcare Workers West, Nausea, Kidney transplantation, Black box, Cramp, FDA, Ultrafiltration, UFR, Public, Dialysis, Kidney failure, Patient, Black, Risk, Mortality, Blue star, Fresenius, Multimedia, Medical device, Health insurance, Pharmaceutical industry, Food

"We need these modifications to protect dialysis patients and help them make informed choices about the care they receive," said Hortencia Armendariz, Healthcare Justice Director at SEIU-UHW.

Key Points: 
  • "We need these modifications to protect dialysis patients and help them make informed choices about the care they receive," said Hortencia Armendariz, Healthcare Justice Director at SEIU-UHW.
  • More than half of the dialysis machines used worldwide are made by Fresenius Medical Care, according to the company.
  • In the last ten years, Fresenius dialysis machines have had a variety of adverse events reported to the FDA that have resulted in recalls.
  • SEIU-United Healthcare Workers West (SEIU-UHW) is a healthcare justice union of more than 100,000 healthcare workers, patients, and healthcare activists united to ensure affordable, accessible, high-quality care for all Californians, provided by valued and respected healthcare workers.

Global Blood Purification Devices Market Report 2023: Developments in the Absorption, Filtration, and Dialysis Processes Fuel Expansion - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Surgery, Health, Medical Devices, Hospital, Blood, Hypertension, Location, Porter's five forces analysis, Absorption, Kidney failure, Dialysis, Asahi Kasei, Competition, Baxter International, Adsorption, Continuity, Cytosorbents Corporation, Growth, Kidney, Diabetes, SWOT, Filtration, Fresenius, Incidence, USD, D, COVID-19, Pharmaceutical industry, Medical device, Hemoperfusion, Haemonetics, Hemodialysis, Application

The Global Blood Purification Devices Market was valued at USD 13.65 billion in the year 2021.

Key Points: 
  • The Global Blood Purification Devices Market was valued at USD 13.65 billion in the year 2021.
  • Americas region is estimated to hold the maximum share in global Blood Purification Devices followed by Europe & APAC.
  • The report analyses the Blood Purification Devices Market by Application - (Continuous Blood Purification, Hemodialysis, Hemoperfusion).
  • The report analyses the Blood Purification Devices Market by End Users - (Hospitals & Clinics, Dialysis Centres, Others).

Europe Compounding Pharmacies Market Report 2023: Sector to Grow by 8.25% Annually Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Pharmaceutical, McKesson Corporation, United Kingdom, Oral, Omnicell, Fagron, Pain management, Pharmacy, Competition, Allergy, Patient, Growth, Strong Bad Sings (and Other Type Hits), Prevalence, Fresenius, Acquisition, European, USD, Investment, User (computing), COVID-19, Pharmaceutical industry, Lithium, Medicinal plants, Dermatology, Nordic

The European Compounding Pharmacies Market is projected to display significant growth represented by a CAGR of 8.25% during 2023-2028.

Key Points: 
  • The European Compounding Pharmacies Market is projected to display significant growth represented by a CAGR of 8.25% during 2023-2028.
  • The European Compounding Pharmacies Market was valued at USD 3314.80 Million in the year 2021 with Italy holding the largest market share.
  • The report analyses the Europe Compounding Pharmacies Market by Type (Oral, Topical, Ophthalmic, Injecs, and Others Types).
  • The Europe Compounding Pharmacies Market has been analysed by Country (United Kingdom, Germany, France, Italy, Spain, Russia, Turkey, Benelux, Nordic, and Rest of Europe).

Dialysis Services Market Revenue to Reach USD 87 Billion by 2027. The Market to Offer USD 12 Billion Opportunities in the Next 5 Years - Arizton

Retrieved on: 
Wednesday, December 7, 2022
Dialysis, Fresenius, ADMS, DaVita Inc., Northwest Kidney Centers, Patient, The Rogosin Institute, Fresenius Medical Care, ARC, COVID-19, Growth, Organization, Acquisition, Health insurance

https://www.arizton.com/request-sample/3582

Key Points: 
  • https://www.arizton.com/request-sample/3582
    Due to the growing demand for healthcare services, there has been a significant shift towards ambulatory and mobile care.
  • In India, the NephroPlus company started the dialysis on wheels initiative in dialysis care.
  • In the US, Odulair LLC is one of the well-known mobile dialysis service provider organizations that deliver several dialysis services annually in the US.
  • It is a mobile medical manufacturer pioneer in building commercial mobile dialysis units in the US and international market.